US WorldMeds (USWM) has finalized the acquisition of Adaptimmune Therapeutics plc’s cell-therapy assets, including TECELRA®(afamitresgene autoleucel), lete-cel, afami-cel, and uza-cel. This acquisition, which was announced on July 28, 2025, represents a strategic move by US WorldMeds, a pharmaceutical company known for its focus on rare and specialty treatments, to expand into oncology and cell therapy.
In this transaction, USWM paid $55 million in cash at closing and has committed to additional payments of up to $30 million based on performance milestones related to commercial and regulatory achievements. Adaptimmune has retained rights to its pre-clinical programs, including PRAME- and CD70-directed T-cell therapies, as well as its allogeneic pipeline. TECELRA, one of the key assets acquired, is a T cell immunotherapy designed for the treatment of synovial sarcoma, a rare form of soft tissue cancer.
The other therapies included in the acquisition, lete-cel, afami-cel, and uza-cel, are engineered TCR T-cell therapies currently under investigation for their potential in treating synovial sarcoma. Breck Jones, the CEO of US WorldMeds, expressed enthusiasm about integrating Adaptimmune’s programs and personnel into their organization, aiming to advance these therapies to address critical unmet needs in patient care.
US WorldMeds received financial advisory services from TD Cowen and legal counsel from Ropes & Gray LLP, while Gibson, Dunn & Crutcher LLP provided legal guidance to the company. The debt financing for this acquisition was led by funds managed by Oaktree Capital Management, L.P., with participation from funds managed by Athyrium Capital Management, LP.
Overall, this acquisition marks a significant step for US WorldMeds, ushering the company into the realm of oncology and cell therapy, broadening its portfolio beyond rare diseases and bleeding disorders. The integration of Adaptimmune’s assets and expertise is poised to drive innovation and progress in the field of cancer treatment, particularly targeting conditions like synovial sarcoma.
Key Takeaways:
– US WorldMeds has successfully acquired Adaptimmune Therapeutics’ cell-therapy assets, signaling a strategic expansion into oncology and cell therapy.
– The acquisition includes TECELRA®(afamitresgene autoleucel) and other TCR T-cell therapies aimed at treating synovial sarcoma, a rare form of soft tissue cancer.
– USWM paid $55 million upfront with potential additional payments of up to $30 million based on performance milestones.
– The debt financing for this acquisition was led by Oaktree Capital Management, L.P., demonstrating confidence in the potential of these cell therapies.
Read more on lanereport.com